LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Search

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.39 -0.42

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.37

Max

2.55

Põhinäitajad

By Trading Economics

Sissetulek

22M

9.7M

Müük

586K

718K

Kasumimarginaal

1,345.822

Töötajad

23

EBITDA

-152K

-12M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+90.59% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. mai 2026

Turustatistika

By TradingEconomics

Turukapital

197M

336M

Eelmine avamishind

2.81

Eelmine sulgemishind

2.39

Uudiste sentiment

By Acuity

67%

33%

311 / 350 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. märts 2026, 18:58 UTC

Suurimad hinnamuutused turgudel

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

24. märts 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. märts 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

24. märts 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Rises, Boosted by Dollar Weakness -- Market Talk

24. märts 2026, 23:16 UTC

Market Talk

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

24. märts 2026, 21:44 UTC

Market Talk

Global Equities Roundup: Market Talk

24. märts 2026, 21:44 UTC

Market Talk

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

24. märts 2026, 20:59 UTC

Tulu

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

24. märts 2026, 20:58 UTC

Uudisväärsed sündmused

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

24. märts 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

24. märts 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

24. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. märts 2026, 20:25 UTC

Tulu

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

24. märts 2026, 20:15 UTC

Market Talk
Uudisväärsed sündmused

Global Commodities Roundup: Market Talk

24. märts 2026, 20:10 UTC

Market Talk

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q Sales $378.7M >WOR

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q Adj EPS 98c >WOR

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q EPS 92c >WOR

24. märts 2026, 19:25 UTC

Market Talk
Uudisväärsed sündmused

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

24. märts 2026, 19:06 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

24. märts 2026, 18:51 UTC

Market Talk
Uudisväärsed sündmused

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

24. märts 2026, 18:40 UTC

Market Talk
Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

24. märts 2026, 18:40 UTC

Market Talk
Uudisväärsed sündmused

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

24. märts 2026, 18:34 UTC

Uudisväärsed sündmused

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

24. märts 2026, 18:27 UTC

Market Talk

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

24. märts 2026, 18:21 UTC

Market Talk
Uudisväärsed sündmused

Silver Snaps 9-Session Losing Streak -- Market Talk

24. märts 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

90.59% tõus

12 kuu keskmine prognoos

Keskmine 4.86 USD  90.59%

Kõrge 7 USD

Madal 2.3 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

311 / 350 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat